Drug Industry focused on high profits and rapid growth.

According to a financial analysis for the listed drug makers having a fiscal year ended at Dec. 31, the business performance during the first quarter of this year showed a remarkable growth in its sales and profits.

Dong-A achieved 124.8 billion won of the sales, which was 2.1% up from the previous year period of 122.2 billion won due to favorable Circulan sales and others but 38% down of th...